Belviq (lorcaserin) Lawsuits
Levin Sedran & Berman LLP is currently investigating potential lawsuits regarding the prescription weight-loss drug Belviq (lorcaserin), which has been linked to development of several forms of cancer.
Due to concerns over the linkage to cancer, the Food and Drug Administration (FDA) asked the drug’s manufacturer, Arena Pharmaceuticals, to voluntarily withdraw Belviq from the market in 2020. While Arena Pharmaceuticals (and their parent company Eisai, Inc.) dispute the linkage of Belviq to the development of cancer, they complied with the FDA’s request.
IMPORTANT: The information provided on this website is not a substitute for professional medical advice. If you are currently experiencing any side effect from Belviq, contact a healthcare professional immediately. Do not stop taking prescription medications like Belviq without talking to your doctor or healthcare provider.
Have you been diagnosed with cancer after taking Belviq?
If you or a loved one have had a diagnosis of cancer after taking the drug Belviq, you may be able to seek financial compensation through a Belviq lawsuit. Levin Sedran & Berman LLP attorneys are currently evaluating lawsuits for various cancers, including but not limited to:
- Lung Cancer
- Pancreatic Cancer
- Colorectal Cancer
If you have questions about a potential Belviq lawsuit, contact our attorneys today for a free case evaluation. We take pride in providing honest case evaluations and there is no obligation to sign with us if you call. If you think you may have a case, don’t wait –talk to a Belviq attorney today.
Call Us To Speak With an Belviq AttorneyContact us about a Belviq Lawsuit
What Is Belviq (lorcaserin)?
Belviq is a prescription weight management medication first approved by the Food & Drug Administration (FDA) in 2012 for use with a reduced-calorie diet and increased physical activity to help weight loss in adults who are obese or are overweight and have weight-related medical problems. Belviq works by increasing feelings of fullness so that less food is eaten. It was available as a tablet (Belviq) and an extended-release tablet (Belviq XR).
As part of Belviq’s approval process, the FDA required Eisai, Inc. (the parent company of Arena Pharmaceuticals) to conduct a randomized, double-blind, placebo-controlled clinical trial to evaluate the risk of heart-related problems. In this trial, which was conducted in approximately 12,000 participants over 5 years, more patients taking Belviq were diagnosed with cancer compared to patients taking placebo, which is an inactive treatment. The incidence of cancer in the trial participants given Belviq was 8%, which was about 10% higher than in the participants given a placebo.
On January 14, 2020, the FDA issued a Drug Safety Communication to Belviq patients, health providers and pharmacies alerting them of the possible increased risk of cancer discovered in the safety trial. On February 13, 2020, after review of the preliminary trial results, the FDA concluded that the risks of taking Belviq outweighed the drug’s benefits and requested that Belviq and Belviq XR be withdrawn from the U.S. market.